Ryan Cross the Science Boss
@rlcscienceboss
Senior Science Correspondent for @Endpts covering biotech, drug discovery, gene editing, RNA, and more. Formerly at Boston Globe and C&EN. Threads: ryancross
ID: 3056932372
23-02-2015 19:27:42
2,2K Tweet
4,4K Takipçi
853 Takip Edilen
A promising new approach that could slow, stop or prevent nerves from dying in diseases like ALS may get its first test in patients next year. Nura Bio raised $68M for clinical tests of its SARM1 inhibitor to stop nerve degeneration. Read more in Endpoints News endpts.com/nura-bio-raise…